Gene expression signature of chronic lymphocytic leukaemia with Trisomy 12

Background  The prognosis of chronic lymphocytic leukaemia (CLL) patients is largely determined by the karyotype of the malignant clone. We have investigated the gene expression profile associated with trisomy 12 (+12).

[1]  M. Hallek,et al.  Disruption of T cell suppression in chronic lymphocytic leukemia by CD200 blockade. , 2009, Leukemia research.

[2]  M. Gorrese,et al.  CD200: a New Target for Immunotherapy in Hematologic Malignancies. , 2008 .

[3]  Sharmistha Pal,et al.  Protein Arginine Methyltransferase 5 Suppresses the Transcription of the RB Family of Tumor Suppressors in Leukemia and Lymphoma Cells , 2008, Molecular and Cellular Biology.

[4]  A. Órfão,et al.  Impact of trisomy 12, del(13q), del(17p), and del(11q) on the immunophenotype, DNA ploidy status, and proliferative rate of leukemic B‐cells in chronic lymphocytic leukemia , 2008, Cytometry. Part B, Clinical cytometry.

[5]  A. Kretz-Rommel,et al.  Blockade of CD200 in the Presence or Absence of Antibody Effector Function: Implications for Anti-CD200 Therapy , 2008, The Journal of Immunology.

[6]  A. Kretz-Rommel,et al.  Rationale for anti-CD200 immunotherapy in B-CLL and other hematologic malignancies: new concepts in blocking immune suppression , 2008, Expert opinion on biological therapy.

[7]  U. Jäger,et al.  Impact of cytogenetic and molecular prognostic markers on the clinical management of chronic lymphocytic leukemia , 2008, Haematologica.

[8]  T. Haferlach,et al.  Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgVH status and immunophenotyping , 2007, Leukemia.

[9]  J. Dickenson,et al.  Functional expression of the P2Y14 receptor in human neutrophils. , 2006, European journal of pharmacology.

[10]  O. Wagner,et al.  Deregulated expression of fat and muscle genes in B-cell chronic lymphocytic leukemia with high lipoprotein lipase expression , 2006, Leukemia.

[11]  P. Bierman,et al.  Genomic abnormalities in chronic lymphocytic leukemia influence gene expression by a gene dosage effect. , 2006, International journal of molecular medicine.

[12]  E. Montserrat,et al.  Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. , 2005, Blood.

[13]  H. Döhner,et al.  Evidence for distinct pathomechanisms in genetic subgroups of chronic lymphocytic leukemia revealed by quantitative expression analysis of cell cycle, activation, and apoptosis-associated genes. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  R. Abseher,et al.  Microarray gene expression profiling of B-cell chronic lymphocytic leukemia subgroups defined by genomic aberrations and VH mutation status. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  F. Ajchenbaum‐Cymbalista,et al.  Binet's staging system and VH genes are independent but complementary prognostic indicators in chronic lymphocytic leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  F. Mancini,et al.  Chronic lymphocytic leukemia patients with highly stable and indolent disease show distinctive phenotypic and genotypic features. , 2003, Blood.

[17]  Axel Benner,et al.  Stromal-derived factor 1 inhibits the cycling of very primitive human hematopoietic cells in vitro and in NOD/SCID mice. , 2002, Blood.

[18]  D. Oscier,et al.  Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. , 2002, Blood.

[19]  D. Oscier,et al.  CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. , 2002, Blood.

[20]  L. Bullinger,et al.  Genetics of chronic lymphocytic leukemia: genomic aberrations and VH gene mutation status in pathogenesis and clinical course , 2002, Leukemia.

[21]  R. Rosenquist,et al.  CD38 expression is a poor predictor for VH gene mutational status and prognosis in chronic lymphocytic leukemia. , 2001, Blood.

[22]  U. Jaeger,et al.  Association of CD38 Antigen Expression with Other Prognostic Parameters in Early Stages of Chronic Lymphocytic Leukemia , 2001, Leukemia & lymphoma.

[23]  A Benner,et al.  Genomic aberrations and survival in chronic lymphocytic leukemia. , 2000, The New England journal of medicine.

[24]  T. Kipps.  Chronic lymphocytic leukemia , 1997, Current opinion in hematology.

[25]  T J Hamblin,et al.  Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. , 1999, Blood.

[26]  E. Thiel,et al.  Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia. , 1999, Blood.

[27]  N. Chiorazzi,et al.  Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. , 1999, Blood.

[28]  T Tango,et al.  Equivalence test and confidence interval for the difference in proportions for the paired-sample design. , 1997, Statistics in medicine.

[29]  M. James,et al.  11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. , 1997, Blood.

[30]  C. Gasche,et al.  Soluble CD23 reliably reflects disease activity in B-cell chronic lymphocytic leukemia. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Ciril Rozman,et al.  Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance , 1986, British journal of haematology.

[32]  J. Binet,et al.  A clinical staging system for chronic lymphocytic leukemia. Prognostic significance , 1977, Cancer.

[33]  D C Case,et al.  Clinical staging of chronic lymphocytic leukemia. , 1977, The Journal of the Maine Medical Association.